Many of Traphaco's products are the result of research by a team of scientists and modern laboratories following the strategy of developing high-end oriental medicine.
Products of high scientific and technological content
According to Ms. Dao Thuy Ha, Deputy General Director of Traphaco, large investment in R&D is one of the proofs that Traphaco's products always have high technology content and top quality.
Along with the research system, Traphaco has invested a large amount of money in quality control activities (QC - Quality Control).
At Traphaco, products are the synchronization of high quality from raw materials, technology and throughout the distribution journey. Each product is the result of thorough research and is subject to strict quality control.
Ms. Ha shared that Traphaco has officially announced its business restructuring plan with the strategy: "Maintaining the leading position in Oriental medicine - Investing in development beyond Oriental medicine". Traphaco's value chain has also been divided accordingly, and the new Marketing strategy "Elevating the Traphaco brand" has been implemented through reflecting the capacity to produce high-quality Western medicine and developing high-end Oriental medicine - maintaining the position of leading Oriental medicine in Vietnam.
With high-end oriental medicine, Traphaco team constantly researches, pioneers in applying solutions, optimizes technology transfer processes, and new products to create a generation of Premium products - a high-end oriental medicine line unique to Traphaco.
Based on GACP medicinal herbs and the quintessence of Vietnamese oriental medicine, Traphaco adds value to the product, in order to meet the higher demands of the high-end consumer segment.
Sales exceeded expectations
Sales of new products in liver supplements and other therapeutic groups have exceeded 1.6 times the expected sales by the beginning of 2023.
Traphaco's heavy investment in in-depth scientific research has brought more advanced and effective products to users.
After a process of cooperation with domestic experts (Institute of Medicinal Materials, Ministry of Health) and foreign experts, most recently, at the Asian Pharmaceutical Conference (AFPS) 2023, held in Hanoi last November, Traphaco had professional reports on medicinal materials.
One of the studies that received attention at the conference was the research project to isolate new compounds in the extract of Rau dang dat - a medicinal plant in the growing area developed by Traphaco in Phu Yen.
According to the study, a new saponin compound (Traphanoside GO1, TRA GO1) and four known compounds (TRA-GO2 - TRAGO5) were isolated from the extract of Rau dang dat. Rau dang dat extract and compounds isolated from the aerial part of Rau dang dat may be helpful in combating obesity and fatty acid metabolism disorders.
Over 50 years of maintaining the brand
Always aiming to become a leading enterprise in the pharmaceutical industry, leading the way in Oriental medicine and strongly developing Western medicine, Traphaco utilizes important resources so that the products are always of optimal quality.
With products that are decades old, scientists at Traphaco and scientists accompanying Traphaco are always researching, searching and finding the best advantages of high-quality medicinal herbs that meet GACP WHO standards, to create high-end product lines (Premium) with even more advantages in terms of effects.
Boganic Premium is a high-end liver support product that has been carefully refined by Traphaco. It is a special product line that the company has invested in research and preparation. It has a unique formula that supports liver support, liver detoxification, and liver cell protection.
The product has a luxurious and classy identity, has anti-counterfeit stamps and accumulates points, increasing the experience and choice for consumers.
This product is not a medicine and does not replace medicine.
Product of: Traphaco Joint Stock Company
Address: 75 Yen Ninh - Ba Dinh - Hanoi
Phone: 18006612
Advertising license number: 2182/2021/XNQC-ATTP issued by the Ministry of Health on August 4, 2021
Source link
Comment (0)